Indegene（INDGN）株式概要
Indegene Limitedは、インド、米国、欧州、および国際的なライフサイエンス商業化企業として事業を展開している。 詳細
報酬
リスク分析
リスクチェックの結果、INDGN 、リスクは検出されなかった。
INDGN Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
₹808.94
FV
36.0% 割安 内在価値ディスカウント15.98%
Revenue growth p.a.
203
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Indegene Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ₹517.55 |
| 52週高値 | ₹632.90 |
| 52週安値 | ₹414.00 |
| ベータ | 0.76 |
| 1ヶ月の変化 | 5.25% |
| 3ヶ月変化 | 4.93% |
| 1年変化 | -14.36% |
| 3年間の変化 | n/a |
| 5年間の変化 | n/a |
| IPOからの変化 | 14.50% |
最新ニュース
ナラティブの更新 • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.分析記事 • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...ナラティブの更新 • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).ナラティブの更新 • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
新しいナラティブ • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Recent updates
ナラティブの更新 • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.分析記事 • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...ナラティブの更新 • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).ナラティブの更新 • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.新しいナラティブ • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Mar 24
INDGN: Steady Fair Value And Upcoming Board Review Will Support Upside Potential
Analysts have kept Indegene's fair value estimate steady at ₹603.0, with only marginal tweaks to assumptions such as the discount rate and future P/E. This reflects fine tuning of their valuation framework rather than a major shift in view.
新しいナラティブ • Mar 14
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.ナラティブの更新 • Mar 05
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have trimmed their price target for Indegene slightly from about ₹606 to ₹603, reflecting modest tweaks to fair value, discount rate and future P/E assumptions while keeping revenue growth and profit margin expectations effectively unchanged. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for the quarter ended December 31, 2025 under IND AS, along with the auditors' limited review report (Key Developments).ナラティブの更新 • Feb 19
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Analysts have kept their fair value estimate for Indegene steady at ₹605.86 per share, with only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding this price target reaffirmation. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for Indegene and its subsidiaries for the quarter ended December 31, 2025, prepared under IND AS, along with the auditors' limited review report (company filing).ナラティブの更新 • Feb 04
INDGN: Upcoming Board And Shareholder Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene from ₹609.63 to ₹605.86, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A board meeting is scheduled for January 29, 2026, to review unaudited consolidated financial results for the quarter ended December 31, 2025, under INDAS, along with the auditors' limited review report (company filing).分析記事 • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...ナラティブの更新 • Jan 08
INDGN: Expanded Consulting Practice And Upcoming Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene slightly from ₹610.25 to ₹609.63. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation view broadly intact.ナラティブの更新 • Dec 23
INDGN: Upcoming Board And Shareholder Actions Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have slightly reduced their price target on Indegene by approximately ₹2 to about ₹610, reflecting marginal adjustments to discount rate and profit margin assumptions, along with a modest increase in long term revenue growth expectations. What's in the News Indegene has expanded its Consulting Practice to provide integrated strategy and transformation support for life sciences clients, aiming to deliver both strategic insight and hands on implementation across the value chain (Key Developments).ナラティブの更新 • Dec 09
INDGN: Upcoming Board Meeting Will Drive Continued Positive Momentum
Analysts have modestly raised their price target on Indegene by about 1 percent to approximately $612, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite largely stable profit margin and discount rate assumptions. What's in the News Board meeting scheduled on October 30, 2025 to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025 and consider equity allotments under ESOP 2020 and RSU 2020 schemes (company filing) Expansion of Indegene's Consulting Practice to provide integrated strategy and transformation support for life sciences clients facing large scale, technology driven change across the value chain (company announcement) Strategic partnership with Datavant to integrate its health data network into Indegene's NEXT Patient Recruitment platform, aiming to speed up clinical trial enrollment and improve patient recruitment, particularly in rare diseases (Datavant and company announcement) Valuation Changes The fair value estimate has risen slightly to about ₹612 per share from roughly ₹608 per share, reflecting a modest upward revision.ナラティブの更新 • Nov 25
INDGN: Upcoming Board Meeting and Expansions Will Drive Continued Momentum
Analysts have slightly adjusted their price target for Indegene, lowering it from ₹609.57 to ₹608.14 as a result of modest revisions in growth and profitability assumptions. What's in the News A board meeting is scheduled for October 30, 2025 to consider consolidated and standalone financial results as well as ESOP/RSU allotments (Board Meeting).ナラティブの更新 • Nov 10
INDGN: Rising Revenue and Business Expansion Will Drive Continued Outperformance
Narrative Update on Indegene Price Target Analysts have lowered their price target for Indegene from ₹644.67 to ₹609.57, citing revised expectations on future profitability and growth dynamics. What's in the News Board meeting scheduled for October 30, 2025, to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025.分析記事 • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...分析記事 • Jul 23
Getting In Cheap On Indegene Limited (NSE:INDGN) Is Unlikely
There wouldn't be many who think Indegene Limited's ( NSE:INDGN ) price-to-earnings (or "P/E") ratio of 32.5x is worth...新しいナラティブ • May 11
M&A And Cortex Integration Will Expand Enterprise Opportunities
M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions.分析記事 • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...分析記事 • Feb 25
Indegene Limited's (NSE:INDGN) Price Is Out Of Tune With Earnings
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 26x, you may consider...株主還元
| INDGN | IN Life Sciences | IN 市場 | |
|---|---|---|---|
| 7D | 1.2% | -1.4% | 2.0% |
| 1Y | -14.4% | -0.6% | 0.4% |
業界別リターン: INDGN過去 1 年間で-0.6 % の収益を上げたIndian Life Sciences業界を下回りました。
リターン対市場: INDGNは、過去 1 年間で0.4 % のリターンを上げたIndian市場を下回りました。
価格変動
| INDGN volatility | |
|---|---|
| INDGN Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.8% |
安定した株価: INDGN 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: INDGNの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1998 | 4,158 | Manish Gupta | www.indegene.com |
Indegene Limitedは、インド、米国、欧州、および国際的なライフサイエンス商業化企業として事業を展開している。事業セグメントは3つ：Enterprise Medical Solutions、Enterprise Commercial Solutions、Omnichannel Activation & Others。同社はバイオ医薬品、新興バイオテクノロジー、医療機器企業向けにバイオテクノロジーや医療機器を開発している。また、企業向け商業・医療・臨床ソリューション、オムニチャネル活性化ソリューションも提供している。さらに、NEXTテクノロジープラットフォームも運営している。さらに、分析、技術、商業、医療、規制、安全サービスをライフサイエンスおよびヘルスケア企業に提供している。Indegene Limitedは1998年に設立され、インドのベンガルールを拠点としている。
Indegene Limited 基礎のまとめ
| INDGN 基礎統計学 | |
|---|---|
| 時価総額 | ₹124.22b |
| 収益（TTM） | ₹4.01b |
| 売上高(TTM) | ₹35.11b |
31.0x
PER（株価収益率3.5x
P/SレシオINDGN は割高か？
公正価値と評価分析を参照収益と収入
| INDGN 損益計算書（TTM） | |
|---|---|
| 収益 | ₹35.11b |
| 売上原価 | ₹0 |
| 売上総利益 | ₹35.11b |
| その他の費用 | ₹31.09b |
| 収益 | ₹4.01b |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 16.71 |
| グロス・マージン | 100.00% |
| 純利益率 | 11.43% |
| 有利子負債／自己資本比率 | 0% |
INDGN の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.4%
現在の配当利回り13%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 07:43 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Indegene Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Deep Shah | 360 ONE Capital Market Private Limited |
| Rajiv Berlia | Citigroup Inc |